# US 2023/0057085 A1 · Therapeutic nuclease compositions and methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0057085 A1
- Document ID: US20230057085A1
- Status: Published application
- Kind: A1
- Application number: 17/696,364
- Filed: 2022-03-16
- Published: 2023-02-23
- Earliest claimed: 2009-11-02
- Assignees: University of Washington through its Center for Commercialization
- Applicants: University Of Washington Through Its Center For Commercialization
- Inventors: Jeffrey A. Ledbetter; Martha Hayden-Ledbetter; Keith Elkon; Xizhang Sun
- Web page: https://patentgrep.com/patent/US20230057085A1

## CPC

- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/14: of the thyroid hormones, e.g. T3, T4
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/06: Antianaemics
- A61P 13/12: of the kidneys
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 15/08: for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A61P 15/10: for impotence
- A61P 15/12: for climacteric disorders
- A61P 17/00: Drugs for dermatological disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 21/04: for myasthenia gravis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07K 16/18: against material from animals or humans
- C12N 9/96: Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
- C12N 11/06: attached to the carrier via a bridging agent
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C12Y 301/27005: Pancreatic ribonuclease (3.1.27.5)
- Y02P 20/582: Recycling of unreacted starting or intermediate materials
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12Y: ENZYMES
- Y02P: CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS

## Abstract

Hybrid nuclease molecules and methods for treating an immune-related disease or disorder in a mammal, and a pharmaceutical composition for treating an immune-related disease in a mammal.

## Claims

### Claim at position 1

1-63. (canceled)

### Claim 64

A method for treating lupus nephritis in a subject in need thereof, comprising administering to the subject a composition comprising:
a polypeptide comprising human RNase 1 operatively coupled with or without a linker to the N-terminus of an Fc domain, and DNase operatively coupled with or without a linker to the C-terminus of the Fc domain, wherein the Fc domain is a human immunoglobulin Fc domain or a mutant human immunoglobulin Fc domain, and wherein the human immunoglobulin Fc domain or mutant human immunoglobulin Fc domain comprises at least one hinge region; and
a pharmaceutically acceptable carrier,
such that treatment occurs.

### Claim 65 (depends on 64)

The method of claim 64, wherein the Fc domain is a mutant human IgG1 Fc domain comprising one or more of the mutations selected from P238S, P331S, K322S, N297S, wherein numbering is according to the EU index.

### Claim 66 (depends on 64)

The method of claim 64, wherein the Fc domain comprises a mutant human IgG1 Fc domain comprising a substitution of one or more of three hinge region cysteine residues with serine.

### Claim 67 (depends on 64)

The method of claim 64, wherein the human RNase 1 comprises the amino acid sequence set forth in SEQ ID NO:149, with or without a leader sequence.

### Claim 68 (depends on 64)

The method of claim 64, wherein the Fc domain comprises a human IgG1 Fc domain.

### Claim 69 (depends on 64)

The method of claim 64, wherein the Fc domain is a mutant Fc domain that has reduced binding to Fc receptors on human cells.

### Claim 70 (depends on 64)

The method of claim 64, wherein the Fc domain comprises the amino acid sequence set forth in SEQ ID NO:145.

### Claim 71 (depends on 64)

The method of claim 64, wherein the DNase comprises:
(a) the amino acid sequence set forth in SEQ ID NO: 143; or
(b) a G105R mutation as set forth in SEQ ID NO: 142; or
(c) mutations G105R and A114F as set forth in SEQ ID NO: 139.

### Claim 72 (depends on 64)

The method of claim 64, wherein the polypeptide comprises a first linker domain, a second linker domain, or both, wherein when the polypeptide comprises a first linker domain, the human RNase 1 is operatively coupled to the Fc domain by the first linker domain, and when the polypeptide comprises a second linker domain, the DNase is operatively coupled to the Fc domain by the second linker domain.

### Claim 73 (depends on 72)

The method of claim 72, wherein the first linker domain, the second linker domain, or both, comprise a gly/ser peptide.

### Claim 74 (depends on 72)

The method of claim 72, wherein the first linker domain, the second linker domain, or both, comprise an NLG peptide comprising the amino acid sequence set forth in SEQ ID NO: 168.

### Claim 75 (depends on 64)

The method of claim 64, wherein the polypeptide comprises a dimeric polypeptide.

### Claim 76 (depends on 64)

The method of claim 64, wherein the composition is formulated for intravenous administration.

### Claim 77

A method for treating lupus nephritis in a subject in need thereof, comprising administering to the subject a composition comprising:
(a) a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 151, SEQ ID NO: 152, or SEQ ID NO: 153, with or without a leader sequence; or
(b) a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 151, SEQ ID NO: 152, or SEQ ID NO: 153, with or without a leader sequence and comprising one or more Fc mutations selected from P238S, P331S, K322S, and N297S, numbering according to EU index; and
a pharmaceutical carrier,
such that treatment occurs.

### Claim 78 (depends on 77)

The method of claim 77, wherein the Fc domain comprises a mutant human IgG1 Fc domain comprising a substitution of one or more of three hinge region cysteine residues with serine.

### Claim 79 (depends on 77)

The method of claim 77, wherein the polypeptide comprises a dimeric polypeptide.

### Claim 80 (depends on 77)

The method of claim 77, wherein the composition is formulated for intravenous administration.

### Claim 81

A method for treating lupus nephritis in a subject in need thereof, comprising administering to the subject a composition comprising:
a polypeptide comprising human RNase 1 operatively linked with or without a linker to the N-terminus of a mutant human IgG1 Fc domain, and DNase operatively linked with or without a linker to the C-terminus of the mutant Fc domain, wherein the human RNase 1 comprises the amino acid sequence set forth in SEQ ID NO: 149, with or without a leader sequence, and wherein the DNase comprises the amino acid sequence set forth in SEQ ID NO: 139, and wherein the mutant human IgG1 Fc domain comprises at least one hinge region; and
a pharmaceutically acceptable carrier,
such that treatment occurs.

### Claim 82 (depends on 81)

The method of claim 81, wherein the mutant Fc domain comprises one or more of the mutations selected from P238S, P331S, K322S, and N297S, numbering is according to the EU index.

### Claim 83 (depends on 82)

The method of claim 82, wherein the mutant Fc domain comprises a substitution of one or more of three hinge region cysteine residues with serine.

### Claim 84 (depends on 81)

The method of claim 81, wherein the polypeptide comprises a dimeric polypeptide.

### Claim 85 (depends on 81)

The method of claim 81, wherein the composition is formulated for intravenous administration.
